Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases

Peptides. 2002 Jul;23(7):1323-32. doi: 10.1016/s0196-9781(02)00068-2.

Abstract

Protein aggregation into dense filamentous inclusions is a characteristic feature of many etiologically diverse neurodegenerative disorders including Alzheimer's disease (AD), spongiform encephalopathies, and tauopathies. Thus, beta-amyloid peptide (Abeta) accumulates within senile amyloid plaques in AD, protease-resistant prion protein constitutes the amyloid deposits in spongiform encephalopathies and tau protein gives rise to neurofibrillary tangles (NFT) both in AD and in tauopathies. Curiously, these abnormal protein inclusions contain, in addition to their major peptide components, some associated sulfated glycosaminoglycans (sGAG). Here we discuss the proposal that the binding of sGAG to aggregate-forming peptides may modify the pathogenic process depending on their subcellular localization.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / etiology*
  • Amino Acid Sequence
  • Amyloid beta-Peptides / chemistry
  • Amyloid beta-Peptides / metabolism*
  • Animals
  • Glycosaminoglycans / chemistry
  • Glycosaminoglycans / metabolism*
  • Humans
  • Models, Biological
  • Neurodegenerative Diseases / etiology*
  • Neurofibrillary Tangles / chemistry
  • Neurofibrillary Tangles / metabolism
  • Neurofibrillary Tangles / pathology
  • Plaque, Amyloid / chemistry
  • Plaque, Amyloid / metabolism
  • Plaque, Amyloid / pathology
  • Prions / chemistry
  • Prions / metabolism*
  • Protein Conformation
  • Protein Processing, Post-Translational
  • tau Proteins / chemistry
  • tau Proteins / metabolism*

Substances

  • Amyloid beta-Peptides
  • Glycosaminoglycans
  • Prions
  • tau Proteins